Cargando…

Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis

Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonoda, Hiroyuki, Takahashi, Kenichi, Minami, Kohtaro, Hirato, Toru, Yamamoto, Tatsuyoshi, So, Sairei, Tanizawa, Kazunori, Schmidt, Mathias, Sato, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229961/
https://www.ncbi.nlm.nih.gov/pubmed/35745811
http://dx.doi.org/10.3390/pharmaceutics14061240
_version_ 1784734912521175040
author Sonoda, Hiroyuki
Takahashi, Kenichi
Minami, Kohtaro
Hirato, Toru
Yamamoto, Tatsuyoshi
So, Sairei
Tanizawa, Kazunori
Schmidt, Mathias
Sato, Yuji
author_facet Sonoda, Hiroyuki
Takahashi, Kenichi
Minami, Kohtaro
Hirato, Toru
Yamamoto, Tatsuyoshi
So, Sairei
Tanizawa, Kazunori
Schmidt, Mathias
Sato, Yuji
author_sort Sonoda, Hiroyuki
collection PubMed
description Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervious to the therapeutic benefits of ERT, although ERT via intrathecal and intracerebroventricular routes can be used for some neuronopathic LSDs (in particular, mucopolysaccharidoses). However, the considerable practical issues involved make these routes unsuitable for long-term treatment. Efforts have been made to modify enzymes (e.g., by fusing them with antibodies against innate receptors on the cerebrovascular endothelium) so that they can cross the BBB via receptor-mediated transcytosis (RMT) and address neuronopathy in the CNS. This review summarizes the various scientific and technological challenges of applying RMT to the development of safe and effective enzyme therapeutics for neuronopathic mucopolysaccharidoses; it then discusses the translational and methodological issues surrounding preclinical and clinical evaluation to establish RMT-applied ERT.
format Online
Article
Text
id pubmed-9229961
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92299612022-06-25 Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis Sonoda, Hiroyuki Takahashi, Kenichi Minami, Kohtaro Hirato, Toru Yamamoto, Tatsuyoshi So, Sairei Tanizawa, Kazunori Schmidt, Mathias Sato, Yuji Pharmaceutics Review Enzyme replacement therapy (ERT) has paved the way for treating the somatic symptoms of lysosomal storage diseases (LSDs), but the inability of intravenously administered enzymes to cross the blood–brain barrier (BBB) has left the central nervous system (CNS)-related symptoms of LSDs largely impervious to the therapeutic benefits of ERT, although ERT via intrathecal and intracerebroventricular routes can be used for some neuronopathic LSDs (in particular, mucopolysaccharidoses). However, the considerable practical issues involved make these routes unsuitable for long-term treatment. Efforts have been made to modify enzymes (e.g., by fusing them with antibodies against innate receptors on the cerebrovascular endothelium) so that they can cross the BBB via receptor-mediated transcytosis (RMT) and address neuronopathy in the CNS. This review summarizes the various scientific and technological challenges of applying RMT to the development of safe and effective enzyme therapeutics for neuronopathic mucopolysaccharidoses; it then discusses the translational and methodological issues surrounding preclinical and clinical evaluation to establish RMT-applied ERT. MDPI 2022-06-11 /pmc/articles/PMC9229961/ /pubmed/35745811 http://dx.doi.org/10.3390/pharmaceutics14061240 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sonoda, Hiroyuki
Takahashi, Kenichi
Minami, Kohtaro
Hirato, Toru
Yamamoto, Tatsuyoshi
So, Sairei
Tanizawa, Kazunori
Schmidt, Mathias
Sato, Yuji
Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title_full Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title_fullStr Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title_full_unstemmed Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title_short Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis
title_sort treatment of neuronopathic mucopolysaccharidoses with blood–brain barrier-crossing enzymes: clinical application of receptor-mediated transcytosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229961/
https://www.ncbi.nlm.nih.gov/pubmed/35745811
http://dx.doi.org/10.3390/pharmaceutics14061240
work_keys_str_mv AT sonodahiroyuki treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT takahashikenichi treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT minamikohtaro treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT hiratotoru treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT yamamototatsuyoshi treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT sosairei treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT tanizawakazunori treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT schmidtmathias treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis
AT satoyuji treatmentofneuronopathicmucopolysaccharidoseswithbloodbrainbarriercrossingenzymesclinicalapplicationofreceptormediatedtranscytosis